ENTA

MKT CAP:$309M

Enanta Pharmaceuticals, Inc.

Market Cap

$309M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$13.35-$1.07 (-7.42%)

Apr 23, 2026

Company Details

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, S...

CEO

Jay R. Luly

IPO Date

Mar 21, 2013

Website

www.enanta.com

Key Metrics TTM

Revenue

$67M

+0.6% YoY

Net Income

-$72M

EPS (Diluted)

-$3.35

Free Cash Flow

-$18M

Revenue / Share

$3.13

Gross Margin

100.0%

Operating Margin

-109.1%

Net Margin

-106.8%

FCF Margin

-27.6%

P/S

4.6x

P/E

—

Earnings Reports

Q2 2026

May 11, 2026

PENDING

Q1 2026

Feb 11, 2026

$19M+9.8%EPS -$0.56

FY 2025

Nov 19, 2025

$65M-3.4%EPS -$3.84

Q4 2025

Nov 19, 2025

$15M+3.5%EPS -$0.87

Q3 2025

Aug 13, 2025

$18M+1.9%EPS -$0.86

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 22	$19M	$19M	-$34M
Q3 22	$19M	$19M	-$33M
Q4 22	$20M	$20M	-$27M
Q1 23	$24M	$23M	-$30M
Q2 23	$18M	$17M	-$39M
Q3 23	$19M	$19M	-$37M
Q4 23	$19M	$19M	-$31M
Q1 24	$18M	$18M	-$35M
Q2 24	$17M	$17M	-$33M
Q3 24	$18M	$18M	-$24M
Q4 24	$15M	$15M	-$30M
Q1 25	$17M	$17M	-$24M
Q2 25	$15M	$15M	-$25M
Q3 25	$18M	$18M	-$19M
Q4 25	$15M	$15M	-$18M
Q1 26	$19M	$19M	-$11M

Valuation

Quarter	P/S	P/E
Q2 22	15.2x	—
Q3 22	10.5x	—
Q4 22	12.4x	—
Q1 23	12.1x	—
Q2 23	10.3x	—
Q3 23	5.8x	—
Q4 23	2.8x	—
Q1 24	3.6x	—
Q2 24	4.9x	—
Q3 24	3.8x	—
Q4 24	3.3x	—
Q1 25	1.9x	—
Q2 25	1.8x	—
Q3 25	2.5x	—
Q4 25	5.0x	—
Q1 26	5.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 22	-$26M	-$26M
Q3 22	-$30M	-$30M
Q4 22	-$16M	-$17M
Q1 23	-$36M	-$39M
Q2 23	-$14M	-$16M
Q3 23	-$32M	-$34M
Q4 23	-$22M	-$23M
Q1 24	-$25M	-$26M
Q2 24	-$29M	-$30M
Q3 24	-$15M	-$21M
Q4 24	-$10M	-$19M
Q1 25	-$17M	-$26M
Q2 25	-$13M	-$16M
Q3 25	$18M	$17M
Q4 25	-$6M	-$8M
Q1 26	-$12M	-$12M

Capital Expenditures

Quarter	CapEx
Q2 22	$74.0K
Q3 22	$251.0K
Q4 22	$1M
Q1 23	$3M
Q2 23	$2M
Q3 23	$2M
Q4 23	$1M
Q1 24	$787.0K
Q2 24	$2M
Q3 24	$7M
Q4 24	$9M
Q1 25	$9M
Q2 25	$3M
Q3 25	$155.0K
Q4 25	$1M
Q1 26	$143.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 22	-7.0%	+5.5%
Q3 22	-9.9%	-6.2%
Q4 22	-13.8%	-17.3%
Q1 23	-14.7%	-7.7%
Q2 23	-4.9%	+8.9%
Q3 23	-3.0%	+6.9%
Q4 23	-6.8%	+5.5%
Q1 24	-23.7%	-1.3%
Q2 24	-4.2%	-13.0%
Q3 24	-4.9%	-24.2%
Q4 24	-22.8%	-11.0%
Q1 25	-5.8%	-23.4%
Q2 25	-12.5%	-20.8%
Q3 25	+1.9%	-11.7%
Q4 25	+3.5%	-24.6%
Q1 26	+9.8%	-26.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 22	$6M	34.6%
Q3 22	$8M	39.0%
Q4 22	$7M	33.6%
Q1 23	$7M	30.3%
Q2 23	$7M	41.4%
Q3 23	$7M	37.0%
Q4 23	$7M	35.5%
Q1 24	$8M	45.0%
Q2 24	$6M	32.6%
Q3 24	$5M	30.1%
Q4 24	$8M	52.8%
Q1 25	$6M	33.4%
Q2 25	$5M	31.4%
Q3 25	$4M	22.8%
Q4 25	$4M	26.7%
Q1 26	$4M	20.5%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q2 22	$42M	$10M	—
Q3 22	$39M	—	$12M
Q4 22	$35M	—	$12M
Q1 23	$41M	—	$12M
Q2 23	$43M	—	$13M
Q3 23	$43M	$13M	—
Q4 23	$36M	$14M	—
Q1 24	$36M	$17M	—
Q2 24	$36M	$14M	—
Q3 24	$29M	$13M	—
Q4 24	$31M	$14M	—
Q1 25	$28M	$13M	—
Q2 25	$28M	$11M	—
Q3 25	$27M	$10M	—
Q4 25	$24M	$10M	—
Q1 26	$21M	$9M	—

Revenue Segments

Quarter	License	Royalty
Q1 23	$1M	$23M
Q2 23	—	$18M
Q3 23	—	$19M
Q4 23	—	$19M
Q1 24	—	$18M
Q2 24	—	$17M
Q3 24	—	$18M
Q1 25	—	$17M
Q2 25	—	$15M
Q3 25	—	$18M
Q4 25	—	$15M
Q1 26	—	$19M

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 22	$41M	$239M	$280M
Q3 22	$28M	$225M	$253M
Q4 22	$44M	$205M	$249M
Q1 23	$42M	$172M	$214M
Q2 23	$73M	$137M	$210M
Q3 23	$95M	$291M	$387M
Q4 23	$85M	$285M	$370M
Q1 24	$40M	$297M	$337M
Q2 24	$64M	$237M	$300M
Q3 24	$36M	$194M	$230M
Q4 24	$37M	$211M	$248M
Q1 25	$84M	$132M	$217M
Q2 25	$60M	$133M	$193M
Q3 25	$45M	$159M	$204M
Q4 25	$32M	$157M	$189M
Q1 26	$37M	$148M	$186M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 22	21M	+0.8%	+1.9%
Q3 22	21M	+0.8%	+2.5%
Q4 22	21M	-0.5%	+1.9%
Q1 23	21M	+1.0%	+2.1%
Q2 23	21M	+1.1%	+2.4%
Q3 23	21M	+0.1%	+1.7%
Q4 23	21M	+0.0%	+2.2%
Q1 24	21M	+0.1%	+1.3%
Q2 24	21M	+0.4%	+0.6%
Q3 24	21M	+0.1%	+0.6%
Q4 24	21M	+0.0%	+0.6%
Q1 25	21M	+0.2%	+0.7%
Q2 25	21M	+0.6%	+0.9%
Q3 25	21M	-0.2%	+0.7%
Q4 25	21M	+0.3%	+0.9%
Q1 26	21M	0.0%	+0.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 22	$120.7K	155
Q3 22	$125.7K	155
Q4 22	$127.0K	160
Q1 23	$147.4K	160
Q2 23	$111.2K	160
Q3 23	$118.1K	160
Q4 23	$130.6K	145
Q1 24	$124.2K	145
Q2 24	$117.6K	145
Q3 24	$123.9K	145
Q4 24	$111.5K	131
Q1 25	$129.5K	131
Q2 25	$113.9K	131
Q3 25	$139.8K	131
Q4 25	$126.0K	120
Q1 26	$155.1K	120

Revenue / Employee